Impact Biomedical (IBO) Free Cash Flow (2022 - 2026)
Impact Biomedical's (IBO) quarterly Free Cash Flow came in at $470000.0 in Q2 2026, up 167.72% on a YoY basis from $175554.4 in Q2 2025, and up 201.29% quarter-over-quarter from -$464000.0 in Q1 2026.
Powered by 
Analysis
Impact Biomedical (IBO) Free Cash Flow (2022 - 2026) Analysis & Trends
Impact Biomedical (IBO) has reported Free Cash Flow for 5 consecutive years, with $470000.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Free Cash Flow rose 167.72% year-over-year to $470000.0; the trailing twelve-month figure through Jun 2026 stood at -$508000.0 (up 84.89% YoY), and the FY2025 full-year result was -$1.9 million, up 33.78% from the prior year.
- Free Cash Flow climbed to $470000.0 in Q2 2026 per IBO's latest filing, from -$464000.0 in the prior quarter.
- Across five years, Free Cash Flow topped out at $470000.0 in Q2 2026 and bottomed at -$1.0 million in Q1 2023.
- Historically, Free Cash Flow has averaged -$548250.0 across 5 years, with a median of -$642500.0 in 2023.
- The sharpest annual moves came in 2024 and 2026: Free Cash Flow sank 127.71% in 2024, then soared 167.72% in 2026.
- Over 5 years, Free Cash Flow stood at -$363000.0 in 2022, then retreated by 19.28% to -$433000.0 in 2023, then tumbled by 127.71% to -$986000.0 in 2024, then surged by 110.04% to $99000.0 in 2025, then soared by 374.75% to $470000.0 in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered $470000.0, -$464000.0, and $99000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 3.49 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 3.43 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 1.01 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 572.80 Mn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -563.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 292.04 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 408.00 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -268.64 Mn |
| 10 | Impact Biomedical | 49.63 Mn | 49.62 Mn | 2,000.00 | 470,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 470,000.00 |
| Mar 31, 2026 | -464,000.00 |
| Dec 31, 2025 | 99,000.00 |
| Sep 30, 2025 | -613,000.00 |
| Jun 30, 2025 | -694,000.00 |
| Mar 31, 2025 | -682,000.00 |
| Dec 31, 2024 | -986,000.00 |
| Sep 30, 2024 | -1.00 Mn |
| Jun 30, 2024 | -385,000.00 |
| Mar 31, 2024 | -482,000.00 |
| Dec 31, 2023 | -433,000.00 |
| Sep 30, 2023 | -672,000.00 |
| Jun 30, 2023 | -745,000.00 |
| Mar 31, 2023 | -1.02 Mn |
| Dec 31, 2022 | -363,000.00 |
| Sep 30, 2022 | -802,000.00 |